(Q36636992)

15 August 2017

1 reference

title

Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction (English)

1 reference

15 August 2017

2

Allen D Seftel

1 reference

15 August 2017

Ridwan Shabsigh

1

1 reference

15 August 2017

Raymond C Rosen

3

1 reference

15 August 2017

Hartmut Porst

4

1 reference

15 August 2017

Sanjeev Ahuja

5

1 reference

15 August 2017

Michael C Deeley

6

1 reference

15 August 2017

Carmen S Garcia

7

1 reference

15 August 2017

François Giuliano

8

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

68

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

689-696

1 reference

NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

The worldwide prevalence and epidemiology of erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Anatomy and physiology of erection: pathophysiology of erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Psychogenic erectile dysfunction and ejaculation disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Core document on erectile dysfunction: key aspects in the care of a patient with erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Health outcomes variables important to patients in the treatment of erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

The psychological and interpersonal relationship scales: assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Treatment responsiveness of the Self-Esteem And Relationship questionnaire in erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Cross-cultural development of a quality of life measure for men with erection difficulties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

The effect of erectile dysfunction on quality of life: psychometric testing of a new quality of life measure for patients with erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Deciphering erectile dysfunction drug trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Tadalafil pharmacokinetics in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Onset and duration of action of sildenafil for the treatment of erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Duration of action of sildenafil citrate in men with erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

The efficacy and safety of tadalafil: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

Effect of tadalafil on sexual timing behavior patterns in men with erectile dysfunction: integrated analysis of randomized, placebo controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.009

10.1016/J.UROLOGY.2006.05.009

7 January 2021

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qs4ekwlacjcifm2iofezjc5jqm

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_qs4ekwlacjcifm2iofezjc5jqm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qs4ekwlacjcifm2iofezjc5jqm

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/qs4ekwlacjcifm2iofezjc5jqm

1 reference